Interactive Financial Charts Not Available

Biogen Pharmachem (BIOGEN) | Financial Analysis & Statements

Biogen Pharmachem Industries Inc. | Small-cap | Financial Services

₹0.91

-1.09%

Biogen Pharmachem vs Motilal Oswal Biogen Pharmachem vs Authum Investment Biogen Pharmachem vs Share India Biogen Pharmachem vs Shalimar Agencies Biogen Pharmachem vs Monarch Networth Biogen Pharmachem vs NIFTY 50 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0

Gross Profit -633.0K

Operating Income 13.4M

Net Income 13.4M

EPS (Diluted) ₹0.01

Balance Sheet Metrics

Total Assets 920.2M

Total Liabilities 900.0K

Shareholders Equity 919.3M

Debt to Equity 0.00

Cash Flow Metrics

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Biogen Pharmachem Income Statement From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Revenue i	0	16.1M	6.7M	21.6M	144.7K
Cost of Goods Sold i	1.7M	951.0K	2.0M	20.8M	14.9M
Gross Profit i	-1.7M	15.1M	4.7M	843.0K	-14.8M
Gross Margin % i	0.0%	94.1%	70.4%	3.9%	-10,229.0%
Operating Expenses
Research & Development i	-	-	-	-	-
Selling, General & Administrative i	-	75.0K	20.0K	55.0K	35.0K
Other Operating Expenses i	9.6M	3.5M	2.6M	900.0K	1.2M
Total Operating Expenses i	9.6M	3.6M	2.6M	955.0K	1.2M
Operating Income i	-2.9M	11.6M	2.1M	-112.0K	-16.0M
Operating Margin % i	0.0%	71.9%	31.3%	-0.5%	-11,079.8%
Non-Operating Items
Interest Income i	-	7.8M	0	0	0
Interest Expense i	0	0	0	0	0
Other Non-Operating Income	-	-	-	-	-
Pre-tax Income i	-2.9M	19.3M	4.6M	-86.0K	-16.0M
Income Tax i	0	0	0	0	0
Effective Tax Rate % i	0.0%	0.0%	0.0%	0.0%	0.0%
Net Income i	-2.9M	19.3M	4.6M	-86.0K	-16.0M
Net Margin % i	0.0%	120.2%	68.4%	-0.4%	-11,080.2%
Key Metrics
EBITDA i	-2.9M	19.3M	4.6M	-86.0K	-16.0M
EPS (Basic) i	₹0.00	₹0.03	₹0.01	₹0.00	₹-0.02
EPS (Diluted) i	₹0.00	₹0.03	₹0.01	₹0.00	₹-0.02
Basic Shares Outstanding i	652603000	652603000	652603000	652603000	652603000
Diluted Shares Outstanding i	652603000	652603000	652603000	652603000	652603000

Income Statement Trend

Biogen Pharmachem Balance Sheet From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Assets
Current Assets
Cash & Equivalents i	548.0K	169.0K	1.3M	831.0K	74.4K
Short-term Investments i	19.6M	107.0K	1.2M	811.0K	-
Accounts Receivable i	0	0	0	0	25.4M
Inventory i	0	0	0	0	0
Other Current Assets	5.7M	-	1.0K	1.0K	-1
Total Current Assets i	26.6M	919.0K	1.5M	19.3M	25.6M
Non-Current Assets
Property, Plant & Equipment i	-	-	-	-	-
Goodwill i	0	0	0	0	0
Intangible Assets i	-	-	-	-	-
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	-	-	-	-	-
Total Non-Current Assets i	893.6M	567.3M	546.7M	530.2M	516.9M
Total Assets i	920.2M	568.2M	548.3M	549.5M	542.5M
Liabilities
Current Liabilities
Accounts Payable i	0	0	0	0	608.5K
Short-term Debt i	0	0	0	0	608.5K
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	900.0K	3.0M	2.4M	8.2M	464.0K
Total Current Liabilities i	900.0K	3.0M	2.4M	8.2M	1.1M
Non-Current Liabilities
Long-term Debt i	0	0	0	0	0
Deferred Tax Liabilities i	-	0	0	0	0
Other Non-Current Liabilities	-	-	-	-	-
Total Non-Current Liabilities i	0	0	0	0	0
Total Liabilities i	900.0K	3.0M	2.4M	8.2M	1.1M
Equity
Common Stock i	652.6M	652.6M	652.6M	652.6M	652.6M
Retained Earnings i	-	-87.4M	-106.7M	-111.3M	-111.2M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	919.3M	565.2M	545.9M	541.3M	541.4M
Key Metrics
Total Debt i	0	0	0	0	608.5K
Working Capital i	25.7M	-2.1M	-844.0K	11.2M	24.5M

Balance Sheet Composition

Biogen Pharmachem Cash Flow Statement From 2021 to 2025

Metric	2025	2024	2023	2022	2021
Operating Activities
Net Income i	-2.9M	19.3M	4.6M	-86.0K	-16.0M
Depreciation & Amortization i	-	-	-	-	-
Stock-Based Compensation i	-	-	-	-	-
Working Capital Changes i	-8.0M	352.0K	12.5M	14.7M	54.9M
Operating Cash Flow i	-10.9M	19.7M	17.0M	14.6M	38.9M
Investing Activities
Capital Expenditures i	0	0	0	0	0
Acquisitions i	-184.0M	34.1M	-19.0M	25.4M	-30.4M
Investment Purchases i	-	-	-	-	-
Investment Sales i	-	-	-	-	-
Investing Cash Flow i	-184.0M	34.1M	-19.0M	25.4M	-30.4M
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-	-	-	-	-
Debt Issuance i	-	-	-	-	-
Debt Repayment i	-	-	-	-	-
Financing Cash Flow i	357.0M	0	0	0	-3.1M
Free Cash Flow i	-10.9M	19.7M	17.0M	14.0M	39.5M
Net Change in Cash i	162.1M	53.8M	-2.0M	40.0M	5.4M

Cash Flow Trend

Biogen Pharmachem Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 92.00

Price to Book 0.59

Price to Sales 50.83

PEG Ratio -0.18

Profitability Ratios

Profit Margin 74.09%

Operating Margin 87.17%

Return on Equity -0.32%

Return on Assets -0.32%

Financial Health

Current Ratio 29.51

Debt to Equity 0.00

Beta -0.74

Per Share Data

EPS (TTM) ₹0.01

Book Value per Share ₹1.56

Revenue per Share ₹0.01

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
biogen	830.4M	92.00	0.59	-0.32%	74.09%	0.00
Motilal Oswal	557.1B	20.48	5.03	22.47%	37.00%	138.95
Authum Investment	506.7B	12.39	3.44	28.87%	93.88%	7.18
Share India	33.2B	10.96	1.72	13.95%	24.50%	22.79
Shalimar Agencies	27.0B	645.33	25.93	10.13%	5.31%	64.93
Monarch Networth	26.2B	16.99	3.29	18.73%	47.16%	1.16

Financial data is updated regularly. All figures are in the company's reporting currency.